Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Vaishali S, Mankad"'
Autor:
Vaishali S. Mankad, Amanda Leach, Yue Chang, Ulrika Wählby Hamrén, Alexandre Kiazand, Robert J. Kubiak, Therese Takas, Tonya Villafana, Manish Shroff
Publikováno v:
Pathogens, Vol 13, Iss 6, p 503 (2024)
Background: Nirsevimab is approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season and in children aged ≤24 months who remain vulnerable to seve
Externí odkaz:
https://doaj.org/article/86743bdbdfea4b6889ccb3ced6d076df
Autor:
Bahar Ahani, Kevin M. Tuffy, Anastasia A. Aksyuk, Deidre Wilkins, Michael E. Abram, Ron Dagan, Joseph B. Domachowske, Johnathan D. Guest, Hong Ji, Anna Kushnir, Amanda Leach, Shabir A. Madhi, Vaishali S. Mankad, Eric A. F. Simões, Benjamin Sparklin, Scott D. Speer, Ann Marie Stanley, David E. Tabor, Ulrika Wählby Hamrén, Elizabeth J. Kelly, Tonya Villafana
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-2 (2024)
Externí odkaz:
https://doaj.org/article/62972434e0cc4edfafbaf60c3024f8ec
Autor:
Bahar Ahani, Kevin M. Tuffy, Anastasia A. Aksyuk, Deidre Wilkins, Michael E. Abram, Ron Dagan, Joseph B. Domachowske, Johnathan D. Guest, Hong Ji, Anna Kushnir, Amanda Leach, Shabir A. Madhi, Vaishali S. Mankad, Eric A. F. Simões, Benjamin Sparklin, Scott D. Speer, Ann Marie Stanley, David E. Tabor, Ulrika Wählby Hamrén, Elizabeth J. Kelly, Tonya Villafana
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-10 (2023)
Abstract Nirsevimab is a monoclonal antibody that binds to the respiratory syncytial virus (RSV) fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of nirsevimab or placebo before the
Externí odkaz:
https://doaj.org/article/fb9efa8bfa3c458ebbb25e11a772eeb6
Autor:
Laura L, Hammitt, Ron, Dagan, Yuan, Yuan, Manuel, Baca Cots, Miroslava, Bosheva, Shabir A, Madhi, William J, Muller, Heather J, Zar, Dennis, Brooks, Amy, Grenham, Ulrika, Wählby Hamrén, Vaishali S, Mankad, Pin, Ren, Therese, Takas, Michael E, Abram, Amanda, Leach, M Pamela, Griffin, Tonya, Villafana, Jon, Heinrichs
Publikováno v:
New England Journal of Medicine. 386:837-846
BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life. The efficacy and safety
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5c42be37ddafcb9c4a807fd65747198
https://doi.org/10.1056/nejmoa2110275
https://doi.org/10.1056/nejmoa2110275
Autor:
Laura Hammitt, Ron Dagan, Yuan Yuan, Manuel Baca Cots, Miroslava Bosheva, Shabhir A Mahdi, William J Muller, Heather J Zar, Dennis Brooks, Amy Grenham, Ulrika Wählby Hamrén, Vaishali S Mankad, Pin Ren, Therese Takas, Jon Heinrichs, Amanda Leach, M Pamela Griffin, Tonya L Villafana
Publikováno v:
Open Forum Infectious Diseases
Background Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in infants. Nirsevimab is a single-dose monoclonal antibody with extended half-life that was shown to protect preterm infants 29 to < 35
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e5de174c6dc7ce4e525e7d3c9e87fc4
http://europepmc.org/articles/PMC8644820
http://europepmc.org/articles/PMC8644820
Autor:
Laurie A. Lee, Larry W. Williams, Kevin J. Anstrom, Ginger S. LaBelle, A. Wesley Burks, Vaishali S. Mankad
Publikováno v:
Annals of Allergy, Asthma & Immunology. 100:469-474
Background Open food challenges are a practical alternative to double-blind, placebo-controlled food challenges in confirming clinical sensitivity or tolerance to a food, and the risks associated with open challenges are unknown. Objective To examine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06074f99a0c9fe16453f75326ee70bc5
https://doi.org/10.1016/s1081-1206(10)60473-5
https://doi.org/10.1016/s1081-1206(10)60473-5
Autor:
Todd D. Green, Vaishali S. Mankad, Kevin J. Anstrom, Pamela H. Steele, Virginia S. LaBelle, Laurie A. Lee, Edwin H. Kim, Larry W. Williams, A. Wesley Burks
Publikováno v:
Pediatrics. 120(6)
OBJECTIVE. The goal was to determine whether patients seen in a referral clinic are experiencing initial allergic reactions to peanuts earlier, compared with a similar population profiled at a different medical center 10 years ago, and to investigate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56896407c80488a8aea7b20809eb2071
https://pubmed.ncbi.nlm.nih.gov/18055680
https://pubmed.ncbi.nlm.nih.gov/18055680
Autor:
Vaishali S. Mankad, A. Wesley Burks
Publikováno v:
Clinical reviews in allergyimmunology. 29(1)
Omalizumab, a recombinant humanized monoclonal antibody against immunoglobulin (Ig)E, represents a unique therapeutic approach for the treatment of allergic diseases. This agent acts as a neutralizing antibody by binding IgE at the same site as the h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f1979d753016ce2f254d6226d63cb89
https://pubmed.ncbi.nlm.nih.gov/16222081
https://pubmed.ncbi.nlm.nih.gov/16222081
Autor:
A.W. Burks, T. Green, Vaishali S. Mankad, Larry W. Williams, Kevin J. Anstrom, Laurie A. Lee, Ginger S. LaBelle, Pamela H. Steele
Publikováno v:
Journal of Allergy and Clinical Immunology. 117:S35
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9a9c8e2e918b2e97b4f88f448005f0a
https://doi.org/10.1016/j.jaci.2005.12.142
https://doi.org/10.1016/j.jaci.2005.12.142
Publikováno v:
Pediatrics. 116:538-538
Guerra S, Lohman IC, Halonen M, Martinez FD, Wright AL. Am J Respir Crit Care Med . 2004;169:70–76 To determine if interferon γ (IFNγ) production and soluble CD14 (sCD14) levels correlate longitudinally with the risk of developing recurrent wheez
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b05b39dfe83bd1bb8e5830de3ccd149
https://doi.org/10.1542/peds.2005-0698f
https://doi.org/10.1542/peds.2005-0698f